◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT HIGH

Sertraline

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT HIGH

No psychiatric indication for Dylan; SSRI for healthy adults reduces anabolic drive, blunts emotion, often impairs sexual function. Would change if Dylan developed clinical anxiety/depression unresponsive to behavioral interventions.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT

    No indication. Side effects (libido, emotional blunting, mild cognitive flattening) outweigh benefit absent clinical anxiety/depression.

  • 30-50, executive maintenance
    NOT-RELEVANT

    unless clinical indication.

  • 50+, mild cognitive decline
    NOT-RELEVANT

    for cognition; may be appropriate for late-life depression with caution re: hyponatremia + falls.

  • Anxiety-prone
    STRONG-CANDIDATE

    if anxiety is impairing despite first-line behavioral interventions (CBT, exercise, sleep, ashwagandha). Sertraline + CBT remains gold standard for moderate-severe GAD.

  • High athletic load, tested status
    SKIP-FOR-NOW

    Not banned but reduces competitive drive, sometimes impairs RPE/effort tolerance. Athletes anecdotally report reduced "fight" on SSRIs.

  • Sleep-disordered
    SKIP-FOR-NOW

    Often disrupts sleep architecture (REM suppression); not a sleep aid.

  • Recovery-focused (post-injury, post-illness)
    NOT-RELEVANT

    unless comorbid depression.

  • Strength/anabolic-focused
    SKIP-PERMANENT

    Reduces libido + may modestly suppress testosterone via prolactin elevation.

▸ Subjective experience (deep)

First 1-2 weeks: GI upset (nausea, loose stool), jitteriness/anxiety paradox, mild insomnia or sedation. Weeks 3-6: gradual mood lift in clinical depression/anxiety. Sustained: emotional blunting (60-80% of users report reduced emotional range — both negative and positive), reduced libido (50%+), delayed/anorgasmic (40-60%), mild weight gain (~3-5 kg over 12 months).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Therapeutic effect generally maintained; some develop "poop-out" (loss of efficacy) at 1-3 years requiring switch.
  • Recommended cycle: Not cycled — chronic daily use for clinical indication.
  • Reset protocol: N/A.
▸ Stacking deep dive

Synergistic with

  • CBT/exposure therapy: Synergistic for OCD, PTSD, social anxiety (combination > either alone).

Avoid stacking with

  • MAOIs: Serotonin syndrome — fatal. 14-day washout required.
  • Tramadol, meperidine, MDMA, St John's wort, 5-HTP: serotonin excess.
  • NSAIDs/aspirin: ↑ GI bleed risk via platelet 5-HT depletion.
  • Triptans: theoretical serotonin syndrome (clinical risk low).

Neutral / safe co-administration

Most supplements; magnesium, omega-3, vitamin D fine.

▸ Drug interactions deep dive

Mild CYP2D6 inhibitor at higher doses (>150mg). Less interaction-prone than fluoxetine/paroxetine. Caution with warfarin (↑ bleeding), antipsychotics, TCAs.

▸ Pharmacogenomics

CYP2C19 and CYP2B6 metabolize sertraline. Poor metabolizers (PM) may have higher exposure → start at 12.5mg. Ultrarapid metabolizers may need higher doses. Genotyping (e.g., GeneSight) sometimes used in TRD workups.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx (psychiatrist/PCP) Pharmacy $4-15/mo generic high Standard. Telehealth options (Cerebral, Done — though both have had regulatory issues) available.
▸ Biomarkers to track (deep)
  • Baseline (before starting): PHQ-9, GAD-7, sodium, LFTs, suicide screen.
  • During use: PHQ-9/GAD-7 q4-6 weeks early; sodium at 2 + 8 weeks (esp. elderly); sexual function check at 6-12 weeks.
  • Post-cycle: Reassess symptom return q3 months after taper.
▸ Controversies / open debates Live debate
  • Effect size vs placebo in mild-moderate depression: Kirsch meta-analyses show small effect over placebo; Cipriani disputes this. Current consensus: moderate-severe MDD benefits clearly; mild MDD response close to placebo.
  • PSSD (post-SSRI sexual dysfunction): Persistent dysfunction after discontinuation in a minority — disputed prevalence, likely <1% but real.
  • Pediatric/young-adult suicide signal: FDA black box; some argue net benefit positive when accounting for prevented suicide.
  • Long-term cognitive impact: Mixed; modest evidence of dulling in healthy users but minimal in clinical populations.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT (no indication for Dylan, side-effect burden incompatible with athletic/cognitive optimization use case).
▸ Open questions / gaps Open

Whether short-course (3-6 mo) sertraline for situational anxiety/insomnia in young athletes carries durable downside. PSSD prevalence still poorly characterized.

▸ Sources (full, with our context)
Back to compact view